Obesity

Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.

Patients projected to have increase in body mass index also likely to develop increased plasma glucose levels and have diminished insulin response.

Study compares effectiveness of oral GLP-1 medication over injection.

Determining which patients benefit most from lifestyle, metformin interventions may improve individualized care decisions.

New study suggests improvement in quality of life and obesity seen with liraglutide compared with placebo.

Received a phone call from someone I know. Has not yet come in for a visit. Just called to see if she qualified to come in for a visit. Woman, 68 years of age, denies history of diabetes, hypertension or other health problems, except being overweight. She stated, “Last year my weight was up. I went on a diet because my triglycerides were high, in the 600’s, but they came down to 140’s when I lost 30 pounds last year. I think I gained back about 10 pounds so that would be about 155 pounds now.” I asked her if she’s weighed herself. She said, no, not since I got off the program, but when I was on the program, I weighed daily. You know, I had holidays, travel, I was with a group, paid for the food, so ate what they all ate, then I just couldn’t get back on track.”

Trial results promising, but DKA still a concern with use of new once-daily pills.

Artificial sweeteners may offer short-term weight loss, but at what cost?

The treatment of choice for obese T2D patients is weight loss.

Increase in BMI and A1c leads to coronary issues.